Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

29 Apr 2010 09:02

RNS Number : 0230L
e-Therapeutics plc
29 April 2010
 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Issue of Equity and Director's award of Options

 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

 

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

 

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

 

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

 

Name

Ordinary Shares owned

Options over Ordinary Shares

Number

Number

Exercise Price

Date at which exercisable

Oliver James

38,500

118,020

£0.67

Vested

25,000

£0.385

28 April 2013

Brad Hoy

80,000

£0.375

Vested

25,000

£0.385

28 April 2013

 

 

 

- Ends -

 

 

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

malcolm@etherapeutics.co.uk

+44 (0) 191 233 1317

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

henry.fitzgerald-o'connor@canaccordadams.com

+44 (0) 20 7050 6500

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

simone.elviss@abchurch-group.com

+44 (0) 20 7398 7700

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFSAUFSSESL
Date   Source Headline
16th Dec 202012:38 pmRNSHolding(s) in Company
8th Dec 202011:07 amRNSCOVID-19 Project Update
21st Oct 20209:06 amRNSIssue of Equity
12th Oct 20203:15 pmRNSHolding(s) in Company
12th Oct 20207:00 amRNSAppointment of Ali Mortazavi as CEO
12th Oct 20207:00 amRNSInterim Results for six months ended 31 July 2020
5th Oct 202012:07 pmRNSNotice of Interim Results
28th Sep 20207:00 amRNSExpansion of Scientific Advisory Board
28th Jul 20205:46 pmRNSHolding(s) in Company
23rd Jul 202010:03 amRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20207:01 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSDirector/PDMR Shareholding
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
14th Jul 20204:49 pmRNSExercise of Broker Option and Total Fundraise
9th Jul 20204:47 pmRNSExercise of Broker Option
8th Jul 20204:41 pmRNSSecond Price Monitoring Extn
8th Jul 20204:36 pmRNSPrice Monitoring Extension
8th Jul 20202:05 pmRNSSecond Price Monitoring Extn
8th Jul 20202:00 pmRNSPrice Monitoring Extension
8th Jul 20207:00 amRNSResult of Retail Offer
7th Jul 20205:46 pmRNSRetail Offer
7th Jul 20205:42 pmRNSFundraise of up to £12.4 million
22nd Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20207:00 amRNSCollaboration with Galapagos
3rd Jun 20205:52 pmRNSHolding(s) in Company
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:36 pmRNSPrice Monitoring Extension
2nd Jun 20202:30 pmRNSResults of 2020 Annual General Meeting
28th May 20207:04 amRNSExpansion into RNAi and creation of SAB
18th May 20204:41 pmRNSSecond Price Monitoring Extn
18th May 20204:37 pmRNSPrice Monitoring Extension
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSExperimental testing initiated with WuXi AppTec
15th May 20205:17 pmRNSAnnual General Meeting – Change of Arrangement
15th May 20203:12 pmRNSe-therapeutics to present at Shares Evening
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSAppointment of Chief Business Officer
23rd Mar 20207:00 amRNSAnti-viral drug discovery initiative
17th Mar 20207:00 amRNSResults for the year ended 31 January 2020
11th Mar 20201:30 pmRNSNotification of Full Year Results Date
20th Feb 20206:09 pmRNSHolding(s) in Company
18th Feb 202012:02 pmRNSHolding(s) in Company
11th Feb 202010:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.